Cost-Benefit of Stockpiling Drugs for Influenza Pandemic

oleh: Ran D. Balicer, Michael Huerta, Nadav Davidovitch, Itamar Grotto

Format: Article
Diterbitkan: Centers for Disease Control and Prevention 2005-08-01

Deskripsi

We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.